Calliditas Therapeutics AB (CALT) Gains on EU Licensing Deal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. ENPH
5. HOOD
6. NXPI
7. SPY
8. BA
9. STX
10. CSGP

Go back to Calliditas Therapeutics AB (CALT) Gains on EU Licensing Deal

Calliditas Therapeutics and STADA partner to register and commercialize specialty therapy for IgA Nephropathy in Europe

July 21, 2021 3:05 AM EDT

STOCKHOLM and BAD VILBEL, Germany, July 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT), (Nasdaq Stockholm: CALTX) ("Calliditas") and STADA Arzneimittel AG ("STADA") announced today that they have entered into a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area (EEA) member states, Switzerland and the UK. 

Under the terms of the agreement, Calliditas is entitled receive an initial upfront... More